Translational Development Acquisition Corp.

Translational Development Acquisition Corp. (TDAC) is a blank-check company focused on the life sciences and healthcare sector, with its name signaling a strategic orientation toward opportunities at the intersection of early-stage research and commercial application, a niche commonly associated with biopharmaceutical and medical technology targets. The company filed an amended registration statement on Form S-1/A with the SEC on November 20, 2024, indicating it was actively progressing through the IPO registration process as part of the 2024 SPAC vintage. The vehicle remains in its pre-business-combination phase as it works toward completing its offering. For full sponsor details, deal timeline, and real-time filing alerts on TDAC, sign up for complete data access at SpacDesk.